Pulmonary Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Pulmo BioTech signs agreement with Biotechnology Consulting Poland for commercialization of PulmoBind

Pulmo BioTech signs agreement with Biotechnology Consulting Poland for commercialization of PulmoBind

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough receives FDA recommendation approval for PEGINTRON

Endothelin research update to be presented at APS' 11th International Conference

Endothelin research update to be presented at APS' 11th International Conference

Actelion launches new 20 mcg/mL Ventavis formulation

Actelion launches new 20 mcg/mL Ventavis formulation

Computed tomography angiography can identify abnormalities and injury beyond the pulmonary arteries

Computed tomography angiography can identify abnormalities and injury beyond the pulmonary arteries

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

Complex, eight-hour open procedure removes life-threatening blood clots from 17-year-old's lungs

Complex, eight-hour open procedure removes life-threatening blood clots from 17-year-old's lungs

Study of pulmonary hypertension treatment in sickle cell patients stopped by NHLBI

Study of pulmonary hypertension treatment in sickle cell patients stopped by NHLBI

Severe obesity brings greater risks of health problems during medical procedures

Severe obesity brings greater risks of health problems during medical procedures

Obstructive sleep apnea increases risk of heart and vascular disease

Obstructive sleep apnea increases risk of heart and vascular disease

FDA extends action date for inhaled Treprostinil (Tyvaso) NDA by three months

FDA extends action date for inhaled Treprostinil (Tyvaso) NDA by three months

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

Pulmonary hypertension in children may result from reduced activity of gene regulator

Pulmonary hypertension in children may result from reduced activity of gene regulator

Follow up results from first case of pulmonary hypertension treated with stem cells

Follow up results from first case of pulmonary hypertension treated with stem cells

Researchers look at sildenafil use in cirrhosis patients

Researchers look at sildenafil use in cirrhosis patients

Aires Pharmaceuticals signs license agreement with NIH

Aires Pharmaceuticals signs license agreement with NIH

Cancer drug shows promise as treatment for pulmonary hypertension

Cancer drug shows promise as treatment for pulmonary hypertension

Sildenafil could become a treatment for Duchenne muscular dystrophy

Sildenafil could become a treatment for Duchenne muscular dystrophy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.